AU2017301880C1 - Immunomodulatory polypeptides and related compositions and methods - Google Patents

Immunomodulatory polypeptides and related compositions and methods Download PDF

Info

Publication number
AU2017301880C1
AU2017301880C1 AU2017301880A AU2017301880A AU2017301880C1 AU 2017301880 C1 AU2017301880 C1 AU 2017301880C1 AU 2017301880 A AU2017301880 A AU 2017301880A AU 2017301880 A AU2017301880 A AU 2017301880A AU 2017301880 C1 AU2017301880 C1 AU 2017301880C1
Authority
AU
Australia
Prior art keywords
cells
cell
peptide
binding peptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017301880A
Other languages
English (en)
Other versions
AU2017301880B2 (en
AU2017301880A1 (en
Inventor
Allen Ebens
Collin HAUSKINS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Juno Therapeutics Inc
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of AU2017301880A1 publication Critical patent/AU2017301880A1/en
Application granted granted Critical
Publication of AU2017301880B2 publication Critical patent/AU2017301880B2/en
Publication of AU2017301880C1 publication Critical patent/AU2017301880C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57554—Prolactin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2017301880A 2016-07-29 2017-07-28 Immunomodulatory polypeptides and related compositions and methods Ceased AU2017301880C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369017P 2016-07-29 2016-07-29
US62/369,017 2016-07-29
PCT/US2017/044549 WO2018023093A1 (en) 2016-07-29 2017-07-28 Immunomodulatory polypeptides and related compositions and methods

Publications (3)

Publication Number Publication Date
AU2017301880A1 AU2017301880A1 (en) 2019-02-07
AU2017301880B2 AU2017301880B2 (en) 2021-11-04
AU2017301880C1 true AU2017301880C1 (en) 2022-04-21

Family

ID=59631857

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017301880A Ceased AU2017301880C1 (en) 2016-07-29 2017-07-28 Immunomodulatory polypeptides and related compositions and methods

Country Status (10)

Country Link
US (1) US12304935B2 (https=)
EP (1) EP3490585B1 (https=)
JP (2) JP7295795B2 (https=)
CN (1) CN110087672A (https=)
AU (1) AU2017301880C1 (https=)
CA (1) CA3031955A1 (https=)
ES (1) ES2951552T3 (https=)
MA (1) MA45779A (https=)
MX (1) MX2019001185A (https=)
WO (1) WO2018023093A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US12304935B2 (en) 2016-07-29 2025-05-20 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
JP2020530280A (ja) 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド 免疫刺激性融合分子およびその使用
EA202091984A1 (ru) * 2018-03-14 2021-02-18 Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) Направленная дзетакинами т-клеточная иммунотерапия, нацеленная на рецептор il-13 альфа 2
EP3765041A4 (en) 2018-03-14 2021-12-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
US11319380B2 (en) 2018-06-04 2022-05-03 Precigen, Inc. MUC16 specific chimeric antigen receptors and uses thereof
CN109306016B (zh) * 2018-08-15 2021-10-22 华东师范大学 共表达细胞因子il-7的nkg2d-car-t细胞及其用途
KR20210056377A (ko) * 2018-09-07 2021-05-18 소티오, 엘엘씨 세포내 락테이트 농도를 조절하는 트랜스 대사 분자와 조합된 키메라 수용체 폴리펩타이드 및 이의 치료 용도
EP3922721A4 (en) * 2019-03-12 2023-01-11 Chongqing Precision Biotech Company Limited PROMOTER REGULATED BY HYPOXIA AND ITS APPLICATION
CN111848811B (zh) * 2019-04-27 2024-10-01 张晋宇 一种蛋白质异二聚体及其用途
EP3969119A1 (en) 2019-05-17 2022-03-23 Xencor, Inc. Il-7-fc-fusi0n proteins
CN112294760B (zh) * 2019-07-26 2025-12-12 宁波新致生物科技有限公司 一种液体制剂及其应用
WO2021081345A1 (en) * 2019-10-25 2021-04-29 Mayo Foundation For Medical Education And Research Bi-peptide with affinity to extracellular matrix proteins or cells and to growth factors for tissue healing and regeneration
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
WO2021115333A1 (zh) * 2019-12-10 2021-06-17 苏州克睿基因生物科技有限公司 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
CN111153961B (zh) * 2020-01-08 2022-02-18 郑州大学 一种亲和pd-1的肽及其应用
JP2023511717A (ja) * 2020-01-30 2023-03-22 パーデュー・リサーチ・ファウンデーション 治療用タンパク質のリガンド媒介性送達およびその使用
CN111533785B (zh) * 2020-02-11 2022-03-08 北京市肿瘤防治研究所 靶向免疫检查点tim3结合肽及其应用
WO2021163874A1 (zh) * 2020-02-18 2021-08-26 苏州工业园区唯可达生物科技有限公司 一种重组病毒载体、包含其的免疫组合物以及用途
EP4146798A4 (en) * 2020-05-04 2025-02-12 Saliogen Therapeutics, Inc. TRANSPOSITION-BASED THERAPIES
CN112063588A (zh) * 2020-08-13 2020-12-11 南京北恒生物科技有限公司 工程化免疫细胞及其用途
US20230364210A1 (en) * 2020-09-17 2023-11-16 Othair Prothena Limited ß-AMYLOID VACCINE FOR THE TREATMENT OF ALZHEIMER’S DISEASE
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
CN118146395A (zh) * 2021-02-08 2024-06-07 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN115029317B (zh) * 2021-02-23 2025-10-28 赛浦生物科技(长春)有限公司 用于过敏性鼻炎的鼻喷雾剂及制备方法
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
JP2024530215A (ja) * 2021-08-13 2024-08-16 上海▲シン▼湾生物科技有限公司 低酸素トリガーの人工転写因子、転写制御システム及びその応用
US20230103980A1 (en) * 2021-10-04 2023-04-06 California Institute Of Technology Thermal state switches in macrophages
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
US20250195658A1 (en) * 2022-01-12 2025-06-19 St. Jude Children's Research Hospital, Inc. Bispecific chimeric antigen receptors targeting grp78 and cd123 or grp78 and b7h3
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
WO2025085672A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b
WO2025129120A2 (en) * 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches for treating autoimmune diseases
CN117986386B (zh) * 2024-02-06 2024-11-29 康立泰生物医药(青岛)有限公司 重组人白细胞介素-35及其制备方法和应用
WO2025176860A1 (en) 2024-02-23 2025-08-28 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Dual chimeric antigen receptor construct targeting cea and epcam

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US6653105B2 (en) 1998-02-11 2003-11-25 Vitagen, Inc. Clonal cells and cell lines derived from C3A cells and methods of making and using them
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
AU3958101A (en) 2000-03-15 2001-09-24 Univ Pohang Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant
EP1268795A2 (en) 2000-03-24 2003-01-02 Bayer Aktiengesellschaft Regulation of human mas oncogene-related g protein-coupled receptor
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
GB0228465D0 (en) 2002-12-06 2003-01-08 Univ Belfast A method of treating disease
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
CA2607954A1 (en) 2005-05-11 2006-11-16 Philogen S.P.A. Conjugate for targeting of drug
PL1966238T3 (pl) * 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
US7833754B2 (en) 2006-01-13 2010-11-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-12 for expression in mammalian cell
WO2008136869A2 (en) 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors
WO2008079973A2 (en) * 2006-12-21 2008-07-03 Centocor, Inc. Egfr binding peptides and uses thereof
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
WO2008134879A1 (en) 2007-05-04 2008-11-13 University Health Network Il-12 immunotherapy for cancer
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
US8715964B2 (en) 2008-05-11 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Expression of IL-12 family heterodimers
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
WO2010126766A1 (en) 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
WO2011112935A2 (en) * 2010-03-12 2011-09-15 The Regents Of The University Of California Antibody fusion proteins with disrupted heparin-binding activity
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
MX2013011363A (es) 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
ES2872964T3 (es) 2011-07-27 2021-11-03 Philogen Spa Inmunoconjugado de IL-12
EP3326467B1 (en) 2011-09-16 2020-03-11 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
CN113684185A (zh) 2013-02-26 2021-11-23 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
CN105518143B (zh) * 2013-03-15 2020-02-21 北京凯得尔森生物技术有限公司 融合蛋白分子和它的使用方法
WO2014183066A2 (en) * 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US12304935B2 (en) 2016-07-29 2025-05-20 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes

Also Published As

Publication number Publication date
CN110087672A (zh) 2019-08-02
EP3490585A1 (en) 2019-06-05
JP7295795B2 (ja) 2023-06-21
JP2023062104A (ja) 2023-05-02
US12304935B2 (en) 2025-05-20
AU2017301880B2 (en) 2021-11-04
MX2019001185A (es) 2019-10-21
WO2018023093A1 (en) 2018-02-01
US20190194283A1 (en) 2019-06-27
JP2019531704A (ja) 2019-11-07
CA3031955A1 (en) 2018-02-01
AU2017301880A1 (en) 2019-02-07
MA45779A (fr) 2019-06-05
ES2951552T3 (es) 2023-10-23
EP3490585B1 (en) 2023-05-17

Similar Documents

Publication Publication Date Title
AU2017301880B2 (en) Immunomodulatory polypeptides and related compositions and methods
AU2016349724B2 (en) Chimeric receptors containing TRAF-inducing domains and related compositions and methods
US20240368625A1 (en) Methods and compositions for preparing genetically engineered cells
JP7832892B2 (ja) Ｌｉｌｒｂ１ベースのキメラ抗原受容体
CN108884164B (zh) 用于免疫疗法的经修饰细胞
JP2021531004A (ja) Ｂｃｍａ特異性を有するキメラ抗原受容体およびその使用
CA2881981A1 (en) Method and compositions for cellular immunotherapy
KR20220146480A (ko) Ｔ 세포 형질도입 방법
WO2022016119A1 (en) Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
US20260061051A1 (en) Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
RU2790444C2 (ru) Способы получения композиций генно-инженерных клеток и родственных композиций
RU2795454C2 (ru) Способы и композиции для получения генно-инженерных клеток
RU2773159C2 (ru) Химерные рецепторы, содержащие traf-6-индуцирующие домены, и связанные с ними композиции и способы
WO2025184421A1 (en) Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
HK40128378A (zh) 对δ样配体3(DLL3)具有特异性的抗体和嵌合抗原受体

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 17 JAN 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 17 JAN 2022

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired